{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:15:54Z","timestamp":1775229354130,"version":"3.50.1"},"reference-count":0,"publisher":"Therapeutic Guidelines Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aust Prescr"],"DOI":"10.18773\/austprescr.2024.013","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T21:03:27Z","timestamp":1713733407000},"page":"66-67","source":"Crossref","is-referenced-by-count":1,"title":["New Drug: Faricimab for neovascular age-related macular degeneration and diabetic macular oedema"],"prefix":"10.18773","volume":"47","member":"39051","published-online":{"date-parts":[[2024,4,23]]},"container-title":["Australian Prescriber"],"original-title":[],"link":[{"URL":"https:\/\/australianprescriber.tg.org.au\/articles\/faricimab-for-neovascular-age-related-macular-degeneration-and-diabetic-macular-oedema.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:37:23Z","timestamp":1775227043000},"score":1,"resource":{"primary":{"URL":"https:\/\/australianprescriber.tg.org.au\/articles\/faricimab-for-neovascular-age-related-macular-degeneration-and-diabetic-macular-oedema.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,4,23]]}},"URL":"https:\/\/doi.org\/10.18773\/austprescr.2024.013","relation":{},"ISSN":["1839-3942"],"issn-type":[{"value":"1839-3942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,23]]}}}